On June 18, 2022, the Centers for Disease Control and Prevention approved Pfizer BioNTech COVID-19 vaccine for children aged 6 months-5 years old, expanding pediatric vaccine eligibility to all children and adolescents age 6 months and older. This vaccine is a 3-dose series. The second dose is three to eight weeks after the first dose, and the third dose more than eight weeks after the second.
On June 24, 2022 the Centers for Disease Control and Prevention approved the Moderna COVID-19 vaccine be used as an option for children ages 6 through 17 years, in addition to its already recommended use in children 6 months through 5 years and adults 18 years and older. This vaccine is a two-dose vaccine series: the second four to eight weeks after the first.
Children who are moderately or severely immunocompromised may need additional doses, as with immunocompromised teens and adults.
Learn more about COVID-19 vaccines for children and teens from the CDC.